NCT06647134

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Detailed description

1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature

Conditions

• Arthritis
• Polymyalgia Rheumatica
• Immune Checkpoint Inhibitors

Timeline

• Start date: 2024-09-11
• Primary completion: 2028-03-31
• Completion: 2028-03-31
• First posted: 2024-10-17
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States